Injection Admin Drugs for Musculoskeletal: 71.4% of denials overturned
In 7 California IMR decisions from 2026 to 2026, reviewers overturned 5 (71.4%). In the last five years: 71.4% of 7. 5 were medical-necessity disputes, 2 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2026 | 7 | 71.4% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 3 | 33.3% | 71.4% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested authorization and coverage for Monovisc injection for knee osteoarthritis. According to the medical literature, viscosupplementation is only recommended for patients with osteoarthritis of the knees with a history of lasting benefit from prior injections, and in patients who have tried and failed all other options and whose remaining options are limited. …”
“The physician reviewer found that a patient has requested authorization and coverage for teriparatide. Severe osteoporosis is defined as a DEXA T‑score more than 2.5 standard deviations below the mean with one or more fragility fractures. The patient meets this definition, with a T‑score of ‑3.6 in the distal one‑third of the left forearm and a history of vertebral compression …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Kevzara. Sarilumab (Kevzara) is U.S. Food and Drug Administration (FDA)-approved and recommended by leading expert guidelines for adult patients with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroids. Corticosteroid-sparing drugs can be effective in achieving …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for ketamine intravenous (IV). In this case, the patient reports pain level primarily involving bilateral scapulae, middle and lower back, hips, and glutes. Treatment trials have included physical therapy, psychotherapy, transcutaneous electrical nerve stimulation (TENS), trigger point injections, and multiple medications. The patient …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Injection Admin Drugs denials for Musculoskeletal overturned?
In 7 California IMR decisions from 2026 to 2026, reviewers overturned 5 (71.4%). In the last five years: 71.4% of 7. 5 were medical-necessity disputes, 2 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.